Literature DB >> 1335101

Molecular diversity of neuronal-type calcium channels identified in small cell lung carcinoma.

M Oguro-Okano1, G E Griesmann, E D Wieben, S J Slaymaker, T P Snutch, V A Lennon.   

Abstract

Using the polymerase chain reaction (PCR), we identified RNA transcripts for two distinct classes of neuronal-type voltage-gated Ca2+ channels (VGCC) in a prototypic small cell lung carcinoma (SCLC) cell line, SCC-9. Oligonucleotide primers were designed to encode amino acid sequences common to alpha 1-subunits of known neuronal VGCC classes. Sequencing of complementary DNA (cDNA) clones derived from two independent PCR products revealed that one corresponded to a brain class A VGCC fragment predicted to encode a P-type VGCC (insensitive to dihydropyridines and omega-conotoxin) characteristic of cerebellar Purkinje cells but not previously identified in humans. The second PCR product was identical (except for one conservative nucleotide difference) to a fragment of the class D VGCC of neurons and neuroendocrine cells, which encodes an L-type VGCC (sensitive to dihydropyridines). By Northern blot analyses, both cDNAs hybridized to messenger RNAs (mRNAs) obtained from SCC-9; class D hybridized additionally to human cerebral cortical mRNA, but neither hybridized to mRNA from the skeletal muscle cell line TE671. Although no cDNA corresponding to class B VGCC (N-type) was identified, SCLCs are known to express VGCC that are sensitive to omega-conotoxin and coprecipitate with 125I-labeled-omega-conotoxin when complexed with serum IgG from patients with the Lambert-Eaton myasthenic syndrome. The multiple classes of neuronal-type VGCC expressed in SCLC could conceivably have both unique and related antigenic determinants that may give rise to antineuronal autoimmune responses. This would account for a spectrum of paraneoplastic neurologic disorders including the Lambert-Eaton syndrome and subacute cerebellar degeneration.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1335101     DOI: 10.1016/s0025-6196(12)61144-6

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  19 in total

1.  Isoform-specific interaction of the alpha1A subunits of brain Ca2+ channels with the presynaptic proteins syntaxin and SNAP-25.

Authors:  J Rettig; Z H Sheng; D K Kim; C D Hodson; T P Snutch; W A Catterall
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

Review 2.  Lambert-Eaton myasthenic syndrome.

Authors:  U Seneviratne; R de Silva
Journal:  Postgrad Med J       Date:  1999-09       Impact factor: 2.401

3.  Ion channels as targets for cancer therapy.

Authors:  Minghua Li; Zhi-Gang Xiong
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2011-06-27

4.  Subacute cerebellar degeneration and Lambert-Eaton myasthenic syndrome associated with antibodies to voltage-gated calcium channels: differential effect of immunosuppressive therapy on central and peripheral defects.

Authors:  J M Goldstein; S G Waxman; T L Vollmer; B Lang; I Johnston; J Newsom-Davis
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-09       Impact factor: 10.154

5.  Low level anti-Hu reactivity: A risk marker for small cell lung cancer?

Authors:  Jeffrey A Tsou; Meleeneh Kazarian; Ankur Patel; Janice S Galler; Ite A Laird-Offringa; Catherine L Carpenter; Stephanie J London
Journal:  Cancer Detect Prev       Date:  2008-12-12

Review 6.  The role of laminins in the organization and function of neuromuscular junctions.

Authors:  Robert S Rogers; Hiroshi Nishimune
Journal:  Matrix Biol       Date:  2016-09-07       Impact factor: 11.583

Review 7.  Autoimmune and paraneoplastic channelopathies.

Authors:  Steven Vernino
Journal:  Neurotherapeutics       Date:  2007-04       Impact factor: 7.620

8.  An improved diagnostic assay for Lambert-Eaton myasthenic syndrome.

Authors:  M Motomura; I Johnston; B Lang; A Vincent; J Newsom-Davis
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-01       Impact factor: 10.154

Review 9.  Immunopathology of the Lambert-Eaton myasthenic syndrome.

Authors:  B Lang; J Newsom-Davis
Journal:  Springer Semin Immunopathol       Date:  1995

10.  Dihydropyrimidine-2-thiones as Eg5 inhibitors and L-type calcium channel blockers: potential antitumour dual agents.

Authors:  Elena González-Hernández; Rubén Aparicio; Mercedes Garayoa; M José Montero; M Ángeles Sevilla; Concepción Pérez-Melero
Journal:  Medchemcomm       Date:  2019-07-04       Impact factor: 3.597

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.